Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Opioid

or Research material

or [[:Category:Antiglaucoma medicines|Antiglaucoma medicine]]

Use the filters below to narrow your results.

Other values:

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Potent mu-opioid receptor agonist (6) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (157) · Mild to moderate pain; cough suppression (low-dose). (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1)

None (157) · Adult: 15–60 mg every 4 hours as needed. (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Ophthalmic: 1 drop 0.5% in affected eye(s) BID (or once daily for XE / Istalol). Oral hypertension: 10 mg PO BID, titrate to 60 mg/day. Migraine prophylaxis: 10 mg BID, titrate to 30 mg/day (1)

None (157) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 5, 10, 20 mg; ophthalmic solution 0.25%, 0.5%; ophthalmic gel-forming solution 0.25%, 0.5% (Timoptic-XE) (1)

None (157) · 360 mg/day (1) · 60 mg/day (oral, hypertension); 0.5% BID (ophthalmic) (1) · N/A (never approved) (1)

None (157) · intranasal; rectal and IV reported. (1) · ophthalmic (1) · Oral (2) · PO (only formulation marketed in the US). (1) · sublingual (1)

None (157) · 30–60 min (PO) (1) · BP effect within hours (oral); IOP reduction within 30 minutes, full effect 1-2 weeks (ophthalmic) (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (157) · 12 hours (oral BID); 24 hours (Timoptic-XE) (1) · 4–6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1)

None (157) · 2.5–3 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~4 hours (oral)'"`UNIQ--ref-0000001B-QINU`"' (1)

None (157) · Not formally characterized in humans. (1) · ~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (157) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (158) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 163 results in range #1 to #163.

1

2

3

4

5

7

7-Hydroxymitragynine

A

B

C

D

E

F

G

GBL

H

Hydromorphone

I

Isopropylphenidate

J

K

Kratom

L

M

N

O

P

R

S

T

U

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"